Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 9.41
CHRS's Cash to Debt is ranked higher than
69% of the 1270 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. CHRS: 9.41 )
CHRS' s 10-Year Cash to Debt Range
Min: 9.41   Max: No Debt
Current: 9.41

Equity to Asset -2.05
CHRS's Equity to Asset is ranked lower than
51% of the 968 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CHRS: -2.05 )
CHRS' s 10-Year Equity to Asset Range
Min: -2.05   Max: -1.72
Current: -2.05

-2.05
-1.72
Z-Score: -0.31
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -188.08
CHRS's Operating margin (%) is ranked higher than
67% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. CHRS: -188.08 )
CHRS' s 10-Year Operating margin (%) Range
Min: -2028.33   Max: -1308.36
Current: -188.08

-2028.33
-1308.36
Net-margin (%) -280.87
CHRS's Net-margin (%) is ranked higher than
65% of the 1045 Companies
in the Global Biotechnology industry.

( Industry Median: -78.17 vs. CHRS: -280.87 )
CHRS' s 10-Year Net-margin (%) Range
Min: -1949.65   Max: -1738.7
Current: -280.87

-1949.65
-1738.7
ROA (%) -294.36
CHRS's ROA (%) is ranked higher than
50% of the 1274 Companies
in the Global Biotechnology industry.

( Industry Median: -27.54 vs. CHRS: -294.36 )
CHRS' s 10-Year ROA (%) Range
Min: -145   Max: -145
Current: -294.36

ROC (Joel Greenblatt) (%) -8366.44
CHRS's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 1243 Companies
in the Global Biotechnology industry.

( Industry Median: -394.00 vs. CHRS: -8366.44 )
CHRS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4130.01   Max: -4130.01
Current: -8366.44

» CHRS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CHRS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 18.99
CHRS's P/S is ranked higher than
77% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 30.34 vs. CHRS: 18.99 )
CHRS' s 10-Year P/S Range
Min: 0   Max: 22.3
Current: 18.99

0
22.3
Current Ratio 0.85
CHRS's Current Ratio is ranked higher than
51% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. CHRS: 0.85 )
CHRS' s 10-Year Current Ratio Range
Min: 0.85   Max: 2.2
Current: 0.85

0.85
2.2
Quick Ratio 0.85
CHRS's Quick Ratio is ranked higher than
53% of the 1262 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. CHRS: 0.85 )
CHRS' s 10-Year Quick Ratio Range
Min: 0.85   Max: 2.2
Current: 0.85

0.85
2.2
Days Sales Outstanding 5.44
CHRS's Days Sales Outstanding is ranked higher than
98% of the 1354 Companies
in the Global Biotechnology industry.

( Industry Median: 116.17 vs. CHRS: 5.44 )
CHRS' s 10-Year Days Sales Outstanding Range
Min: 30.37   Max: 51.08
Current: 5.44

30.37
51.08

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -2.50
CHRS's Earnings Yield (Greenblatt) is ranked higher than
80% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. CHRS: -2.50 )
CHRS' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3   Max: 0
Current: -2.5

-3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
» More Articles for CHRS

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Coherus BioSciences to Present at Cowen and Company Health Care Conference on March 2 Feb 23 2015
Coherus BioSciences to Present at Cowen and Company Health Care Conference on March 2 Feb 23 2015
Lane Bryant sales up, but CEO says it can do better Feb 18 2015
Coherus Biosciences (CHRS) Jumps: Stock Moves Up 12.7% - Tale of the Tape Feb 06 2015
Coherus BioSciences to Present at Leerink Healthcare Conference on February 11 Feb 04 2015
How to Invest in the New Industry of 'Biosimilar' or 'Generic' Biological Drugs Jan 09 2015
Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results Dec 15 2014
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Dec 15 2014
Coherus BioSciences Reports Third Quarter 2014 Financial and Operating Results Dec 15 2014
Q3 2014 Coherus Biosciences Inc Earnings Release - After Market Close Dec 15 2014
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Dec 11 2014
Coherus BioSciences to Present at the J.P. Morgan Healthcare Conference on January 12 Dec 08 2014
Coherus BioSciences to Present at the J.P. Morgan Healthcare Conference on January 12 Dec 08 2014
KKR to Acquire Minority Stake in Arbor Pharmaceuticals Dec 05 2014
Coherus BioSciences to Host Earnings Conference Call on December 15 Dec 04 2014
Coherus BioSciences to Host Earnings Conference Call on December 15 Dec 04 2014
Coherus BioSciences Prices Initial Public Offering of $85 Million of Common Stock Nov 19 2014
Coherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters'... Nov 19 2014
COHERUS BIOSCIENCES, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in... Nov 13 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK